454 related articles for article (PubMed ID: 21258415)
21. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
22. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition.
Xu W; Soga S; Beebe K; Lee MJ; Kim YS; Trepel J; Neckers L
Br J Cancer; 2007 Sep; 97(6):741-4. PubMed ID: 17712310
[TBL] [Abstract][Full Text] [Related]
24. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
25. Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.
Radtke J; Rezaie SG; Kugler Ch; Zabel P; Schultz H; Vollmer E; Goldmann T; Lang DS
Rom J Morphol Embryol; 2010; 51(4):647-53. PubMed ID: 21103621
[TBL] [Abstract][Full Text] [Related]
26. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
27. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
28. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
[TBL] [Abstract][Full Text] [Related]
29. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
[TBL] [Abstract][Full Text] [Related]
30. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
Shimamura T; Lowell AM; Engelman JA; Shapiro GI
Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
[TBL] [Abstract][Full Text] [Related]
31. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
33. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
34. Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.
Morodomi Y; Takenoyama M; Inamasu E; Toyozawa R; Kojo M; Toyokawa G; Shiraishi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Sugio K; Ichinose Y
Anticancer Res; 2014 Jul; 34(7):3825-30. PubMed ID: 24982409
[TBL] [Abstract][Full Text] [Related]
35. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J; Okamoto I; Takezawa K; Sakai K; Azuma K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Janne PA; Nakagawa K
Br J Cancer; 2012 Feb; 106(4):763-7. PubMed ID: 22240786
[TBL] [Abstract][Full Text] [Related]
36. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
Li Y; Ye X; Liu J; Zha J; Pei L
Neoplasia; 2011 Jan; 13(1):1-11. PubMed ID: 21245935
[TBL] [Abstract][Full Text] [Related]
38. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
39. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
[TBL] [Abstract][Full Text] [Related]
40. Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue.
Ulivi P; Puccetti M; Capelli L; Chiadini E; Bravaccini S; Calistri D; Zoli W; Amadori D; Candoli P
J Clin Pathol; 2013 Aug; 66(8):708-10. PubMed ID: 23533259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
